These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 23595874)

  • 21. Do trans fatty acids from industrially produced sources and from natural sources have the same effect on cardiovascular disease risk factors in healthy subjects? Results of the trans Fatty Acids Collaboration (TRANSFACT) study.
    Chardigny JM; Destaillats F; Malpuech-Brugère C; Moulin J; Bauman DE; Lock AL; Barbano DM; Mensink RP; Bezelgues JB; Chaumont P; Combe N; Cristiani I; Joffre F; German JB; Dionisi F; Boirie Y; Sébédio JL
    Am J Clin Nutr; 2008 Mar; 87(3):558-66. PubMed ID: 18326592
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.
    Kastelein JJ; van der Steeg WA; Holme I; Gaffney M; Cater NB; Barter P; Deedwania P; Olsson AG; Boekholdt SM; Demicco DA; Szarek M; LaRosa JC; Pedersen TR; Grundy SM; ;
    Circulation; 2008 Jun; 117(23):3002-9. PubMed ID: 18519851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a).
    Hartgens F; Rietjens G; Keizer HA; Kuipers H; Wolffenbuttel BH
    Br J Sports Med; 2004 Jun; 38(3):253-9. PubMed ID: 15155420
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of Extended-Release Niacin on High-Density Lipoprotein (HDL) Functionality, Lipoprotein Metabolism, and Mediators of Vascular Inflammation in Statin-Treated Patients.
    Yadav R; Liu Y; Kwok S; Hama S; France M; Eatough R; Pemberton P; Schofield J; Siahmansur TJ; Malik R; Ammori BA; Issa B; Younis N; Donn R; Stevens A; Durrington P; Soran H
    J Am Heart Assoc; 2015 Sep; 4(9):e001508. PubMed ID: 26374297
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Theobromine Does Not Affect Fasting and Postprandial HDL Cholesterol Efflux Capacity, While It Decreases Fasting miR-92a Levels in Humans.
    Talbot CPJ; Mensink RP; Smolders L; Bakeroot V; Plat J
    Mol Nutr Food Res; 2018 Jul; 62(13):e1800027. PubMed ID: 29797695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cocoa flavanol-enriched snack bars containing phytosterols effectively lower total and low-density lipoprotein cholesterol levels.
    Polagruto JA; Wang-Polagruto JF; Braun MM; Lee L; Kwik-Uribe C; Keen CL
    J Am Diet Assoc; 2006 Nov; 106(11):1804-13. PubMed ID: 17081832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A systematic review and meta-analysis of randomized controlled trials of the effect of konjac glucomannan, a viscous soluble fiber, on LDL cholesterol and the new lipid targets non-HDL cholesterol and apolipoprotein B.
    Ho HVT; Jovanovski E; Zurbau A; Blanco Mejia S; Sievenpiper JL; Au-Yeung F; Jenkins AL; Duvnjak L; Leiter L; Vuksan V
    Am J Clin Nutr; 2017 May; 105(5):1239-1247. PubMed ID: 28356275
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of low molecular weight procyanidin rich extract from french maritime pine bark on cardiovascular disease risk factors in stage-1 hypertensive subjects: Randomized, double-blind, crossover, placebo-controlled intervention trial.
    Valls RM; Llauradó E; Fernández-Castillejo S; Puiggrós F; Solà R; Arola L; Pedret A
    Phytomedicine; 2016 Nov; 23(12):1451-1461. PubMed ID: 27765365
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regular consumption of cocoa powder with milk increases HDL cholesterol and reduces oxidized LDL levels in subjects at high-risk of cardiovascular disease.
    Khan N; Monagas M; Andres-Lacueva C; Casas R; Urpí-Sardà M; Lamuela-Raventós RM; Estruch R
    Nutr Metab Cardiovasc Dis; 2012 Dec; 22(12):1046-53. PubMed ID: 21550218
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study.
    Tzounis X; Rodriguez-Mateos A; Vulevic J; Gibson GR; Kwik-Uribe C; Spencer JP
    Am J Clin Nutr; 2011 Jan; 93(1):62-72. PubMed ID: 21068351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the effects of diets enriched in lauric, palmitic, or oleic acids on serum lipids and lipoproteins in healthy women and men.
    Temme EH; Mensink RP; Hornstra G
    Am J Clin Nutr; 1996 Jun; 63(6):897-903. PubMed ID: 8644684
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Black tea consumption reduces total and LDL cholesterol in mildly hypercholesterolemic adults.
    Davies MJ; Judd JT; Baer DJ; Clevidence BA; Paul DR; Edwards AJ; Wiseman SA; Muesing RA; Chen SC
    J Nutr; 2003 Oct; 133(10):3298S-3302S. PubMed ID: 14519829
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia.
    Kerzner B; Corbelli J; Sharp S; Lipka LJ; Melani L; LeBeaut A; Suresh R; Mukhopadhyay P; Veltri EP;
    Am J Cardiol; 2003 Feb; 91(4):418-24. PubMed ID: 12586255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pitavastatin: novel effects on lipid parameters.
    Chapman MJ
    Atheroscler Suppl; 2011 Nov; 12(3):277-84. PubMed ID: 22152282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical utility of different lipid measures for prediction of coronary heart disease in men and women.
    Ingelsson E; Schaefer EJ; Contois JH; McNamara JR; Sullivan L; Keyes MJ; Pencina MJ; Schoonmaker C; Wilson PW; D'Agostino RB; Vasan RS
    JAMA; 2007 Aug; 298(7):776-85. PubMed ID: 17699011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lipids and antioxidative effects of estradiol and sequential norethisterone acetate treatment in a 3-month randomized controlled trial.
    Falkeborn M; Lithell H; Persson I; Vessby B; Naessén T
    Climacteric; 2002 Sep; 5(3):240-8. PubMed ID: 12419082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Freeze-dried strawberries lower serum cholesterol and lipid peroxidation in adults with abdominal adiposity and elevated serum lipids.
    Basu A; Betts NM; Nguyen A; Newman ED; Fu D; Lyons TJ
    J Nutr; 2014 Jun; 144(6):830-7. PubMed ID: 24670970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol.
    Bays HE; McKenney JM; Dujovne CA; Schrott HG; Zema MJ; Nyberg J; MacDougall DE;
    Am J Cardiol; 2003 Sep; 92(5):538-43. PubMed ID: 12943873
    [TBL] [Abstract][Full Text] [Related]  

  • 39. On-treatment non-high-density lipoprotein cholesterol, apolipoprotein B, triglycerides, and lipid ratios in relation to residual vascular risk after treatment with potent statin therapy: JUPITER (justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin).
    Mora S; Glynn RJ; Boekholdt SM; Nordestgaard BG; Kastelein JJ; Ridker PM
    J Am Coll Cardiol; 2012 Apr; 59(17):1521-8. PubMed ID: 22516441
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of combination therapy with lipid-reducing drugs in patients with coronary heart disease and "normal" cholesterol levels. A randomized, placebo-controlled trial. Harvard Atherosclerosis Reversibility Project (HARP) Study Group.
    Pasternak RC; Brown LE; Stone PH; Silverman DI; Gibson CM; Sacks FM
    Ann Intern Med; 1996 Oct; 125(7):529-40. PubMed ID: 8815751
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.